Iovance Biotherapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
162.47 |
287.10 |
481.41 |
683.06 |
859.54 |
1,081.88 |
| Przychód Δ r/r |
0.00% |
76.71% |
67.68% |
41.89% |
25.84% |
25.87% |
| Przychód (min) |
160.26 |
257.34 |
375.01 |
671.66 |
733.59 |
923.35 |
| Przychód (max) |
168.37 |
299.42 |
634.11 |
694.46 |
990.26 |
1,246.41 |
| EBITDA (średnia) |
32.49 |
57.42 |
96.28 |
136.61 |
171.91 |
216.38 |
| EBIT (średnia) |
32.49 |
57.42 |
96.28 |
136.61 |
171.91 |
216.38 |
| EBIT % |
20.00% |
20.00% |
20.00% |
20.00% |
20.00% |
20.00% |
| Zysk netto (średni) |
-375.36 |
-326.11 |
-259.21 |
-68.06 |
-24.16 |
1.45 |
| Zysk netto % |
-231.03% |
-113.59% |
-53.84% |
-9.96% |
-2.81% |
0.13% |
| EPS (średnia) |
-1.29 |
-1.12 |
-0.70 |
-0.21 |
-0.08 |
0.01 |
| Liczba analityków (Przychody) |
11 |
9 |
11 |
8 |
6 |
7 |
| Liczba analityków (EPS) |
10 |
8 |
9 |
6 |
3 |
4 |
| symbol |
IOVA |
IOVA |
IOVA |
IOVA |
IOVA |
IOVA |